Effects of a novel DNA-damaging agent on the budding yeast Saccharomyces cerevisiae cell cycle

Laura Popolo, Ferdinando Viganò, Eugenio Erba, Nicola Mongelli, Maurizio D'Incalci

Research output: Contribution to journalArticlepeer-review


We have investigated the effects on Saccharomyces cerevisiae of a novel antitumour agent (FCE24517 or Tallimustine) which causes selective alkylations to adenines in the minor groove of DNA. Tallimustine, added to wild-type cells for short periods, reduced the growth rate and increased the percentage of budded cells and delayed the cell cycle in the late S+G2+M phases. In the rad9Δ null mutant cells, Tallimustine treatment did not affect growth rate and the percentage of budded cells but greatly reduced cell viability compared to isogenic cells. Consistent with a role of RAD9 in inducing a transient delay in G2 phase which preserves cell viability, the potent cytotoxic effect of the drug on rad9Δ cells was alleviated by treatment with nocodazole. Tallimustine was also found to delay the resumption from G1 arrest of wild-type but not of rad9Δ cells. These data indicate that the effects of Tallimustine on cell cycle progression in yeast are mediated by the RAD9 gene product. From our data it appears that yeast could be a valuable model system to study the mode of action of this alkylating drug and of minor groove alkylators in general.

Original languageEnglish
Pages (from-to)349-359
Number of pages11
Issue number4
Publication statusPublished - Mar 30 1996


  • Alkylating agents
  • Cell cycle
  • Checkpoints
  • rad9 mutant
  • Saccharomyces cerevisiae

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Biotechnology
  • Bioengineering
  • Microbiology


Dive into the research topics of 'Effects of a novel DNA-damaging agent on the budding yeast Saccharomyces cerevisiae cell cycle'. Together they form a unique fingerprint.

Cite this